22 Jun, 2026
Jerusalem, Israel – 22.6.2026 – Rafa Laboratories , a global leader in the development, manufacture and supply of medical countermeasures, announces a pivotal three-year agreement with the U.S. Department of Health and Human Services (HHS), Administration for Strategic Preparedness and Response (ASPR) , Strategic National Stockpile (SNS) for the supply of Atropine Autoinjectors (0.5 mg, 1 mg, and 2 mg) for pediatric and adult use. With the United States facing a heightened threat environment driven by the ongoing conflict in Iran and the global visibility surrounding the 2026 FIFA World Cup, preparedness is more critical than ever. This deal, valued at $46 million, will reinforce the nation’s readiness to counteract chemical nerve-agent threats.
A Continuous Partnership
This new contract marks the second long-term supply agreement between Rafa and the SNS, a successful partnership established in 2017.
“This agreement reflects our commitment to maintaining a reliable supply relationship in the years ahead.” said Iddo Leshem, CEO of Rafa Laboratories. “Atropine is the basic layer of protection against chemical nerve agents, and ensuring a robust, readily available supply is critical for national security. We are proud to continue this crucial mission with ASPR covering both adult and pediatric populations.”
Securing Global Role, Driving New Products
This multi-year contract further strengthens Rafa Laboratories’ position as the leading global supplier of CBRN medical countermeasure autoinjectors.
“The success of this partnership sets the stage for the company’s expansion into new product lines and additional therapeutic areas, ” said Roy Shay, VP Biodefense, Rafa Laboratories. Rafa and the Biomedical Advanced Research and Development Authority (BARDA) are currently collaborating to develop a new design for Rafa’s atropine autoinjectors which will be optimally positioned for civilian use, while maintaining the exceptionally high reliability rate of 99.999% successful activation required by the US FDA for emergency use autoinjectors.
Rafa has also been recently awarded an additional landmark development contract by BARDA for the advanced development of a novel intramuscular (IM) formulation of tranexamic acid (TXA)—a potentially life-saving therapy for uncontrolled bleeding. The contract is potentially valued at up to $186 million, including all option periods. Furthermore, Rafa is cultivating an active pipeline and preparing for the launch of additional drug-device combination products such as Naloxone 10 mg autoinjector – an antidote for high-potency opioid poisoning, and a Ketamine autoinjector for the treatment of moderate to severe pain, further diversifying and strengthening global emergency preparedness across a variety of therapeutic needs.
About Rafa Laboratories
Founded in 1937 and headquartered in Jerusalem, Israel, Rafa Laboratories is a global leader in biodefense and emergency medical solutions. For more than 40 years, Rafa has supplied medical countermeasure autoinjectors to the U.S. federal government, NATO allies, military forces, and civilian stockpiles worldwide, including its Midazolam 10 mg autoinjector (US-FDA approved under NDA #216359 since 2022) and Atropine autoinjector (US-FDA approved under NDA #212319 for 2 mg since 2018 and EUA # for 0.5 & 1 mg since 2017). The company’s expertise spans the entire value chain — from a robust R&D pipeline addressing emerging threats, to cGMP-compliant manufacturing and successful regulatory approvals from the U.S. FDA and European health authorities.
Rafa’s controlling shareholder, FIMI Opportunity Funds, is Israel’s leading private equity fund. With over 25 years of experience, FIMI manages assets of $7 billion and has completed nearly 100 investments globally.
